The global non-specific endonuclease market is gaining strong traction as biotechnology and pharmaceutical industries expand their research and manufacturing capabilities. Valued at US$ 364.8 Mn in 2025, the market is projected to reach US$ 726.6 Mn by 2036, registering a healthy CAGR of 6.5% from 2026 to 2036. This growth reflects the increasing demand for high-purity biologics, expanding gene therapy pipelines, and rising adoption of advanced molecular biology techniques.
Understanding the Rol